by McDermott + Bull | May 16, 2024 | Article, Healthcare + Life Sciences, Healthcare + Life Sciences Article, Jake Vander Zanden, Jake Vander Zanden Article
A few weeks ago, McDermott + Bull Interim Leaders and I hosted a small breakfast for C-Level executives in the life sciences sector. Simon Arkell, CEO and Co-Founder of Ryght AI, joined us as our keynote speaker to share his thoughts and insights on AI and its impact...
by McDermott + Bull | Nov 29, 2023 | Article, Healthcare + Life Sciences Article, Jake Vander Zanden, Jake Vander Zanden Article
Recently, my colleague Mark McConnell and I hosted a breakfast meeting with around 40 local C-Suite executives within the life sciences sector. Paul LaViollette, Managing Partner and Chief Operating Officer of SV Health Investors, joined us from Boston to share his...
by McDermott + Bull | Mar 13, 2023 | Healthcare + Life Sciences, Healthcare + Life Sciences Article, Ken Dropiewski, Ken Dropiewski Article
A CONVERSATION WITH RENOWNED VASCULAR SURGEON, DR. FRANK J. VEITH As one of America’s most celebrated surgeons, Dr. Frank Veith’s career was anything but conventional – he’s worked undercover for the CIA, attempted to make Vascular Surgery an independent specialty,...
by McDermott + Bull | Feb 16, 2023 | Article, Healthcare + Life Sciences Article, Jake Vander Zanden, Jake Vander Zanden Article
In 2022, we saw a significant increase in the number of deals by private equity and venture capital firms within the life sciences, medical, and healthcare sectors. This all points toward positive growth, but the biggest challenge PE and VC firms face is seeing a...
by McDermott + Bull | Feb 1, 2023 | Article, Healthcare + Life Sciences, Healthcare + Life Sciences Article, Ken Dropiewski, Ken Dropiewski Article
MEDTECH + LIFE SCIENCES OUTLOOK IN 2023 2022 was an interesting year, to say the least. It was the tale of two markets. After the extremely volatile years of 2020 and 2021, no one could have predicted the sheer amount of momentum that lay ahead in 2022. The economy...
by McDermott + Bull | Nov 24, 2022 | Article, Healthcare + Life Sciences, Healthcare + Life Sciences Article, Ken Dropiewski, Ken Dropiewski Article
Heading into 2022, many expected the rapid continuation of strong initial public offerings (IPOs) and merger + acquisition (M+A) activity. Wow, that was off. The underestimated implications of supply chain issues, geopolitical concerns, and Federal Trade Commission...
